January 14, 2020

iBio’s transformation driven by FastPharming System, 3D bioprinting materials and proprietary therapeutics

iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the initiative is a new brand for its core technology in 2019, the FastPharming ...

Continue Reading

December 9, 2019

Facilitating 3D Organ Printing with Plant-Based BioInks

There is a chronic shortage of organs available for transplant.  Bioprinted organs could dramatically increase accessibility to all patients in need of transplants.  Some simpler biofabricated tissues are already entering the clinic, with the promise of ...

Continue Reading

October 9, 2019

Successfully Addressing the Challenges of Glycosylation

Post-translational modification is a critical step in the synthesis of biotherapeutic molecules. Among these alterations to the original naked protein, glycosylation may be the most significant and difficult to properly complete. In this roundtable, we ...

Continue Reading

July 25, 2019

Reducing Fill-Finish Wait Times

iBio has expanded its CDMO service offerings to include independent sterile liquid cGMP fill-finish services to support the preclinical and clinical trial needs of drug developers. This new service complements iBio’s existing biologics bulk drug ...

Continue Reading

May 30, 2019

The Advantage of Plant-based Expression Solutions Around the Globe

iBio offers development and manufacturing services for biologic drug substances and drug products, built around our proprietary plant-based platform technology. Client support is offered from early development through fill and finish for research-grade, ...

Continue Reading
1 2 3